The pharmaceutical industry has spent more than $100 million in a battle to defeat a California ballot measure that could put price caps on its products.

California voters go to the polls Tuesday to vote on Proposition 61, which would prohibit state medical programs from buying any drug that doesn’t have the same price as those obtained by the U.S. Department of Veterans Affairs.